Northwestern Mutual Wealth Management Co. Buys New Position in Stryker Corporation $SYK

Northwestern Mutual Wealth Management Co. bought a new stake in Stryker Corporation (NYSE:SYK) during the second quarter, Holdings Channel.com reports. The fund bought 45,200 shares of the medical technology company’s stock, valued at approximately $14,231,000.

Several other institutional investors also recently added to or reduced their stakes in SYK. Gables Capital Management Inc. acquired a new position in shares of Stryker during the second quarter worth approximately $25,000. Kilter Group LLC acquired a new stake in shares of Stryker in the second quarter worth $25,000. Godfrey Financial Associates Inc. bought a new position in Stryker during the fourth quarter worth $26,000. Sankala Group LLC bought a new position in Stryker during the fourth quarter worth $26,000. Finally, United Financial Planning Group LLC acquired a new position in Stryker during the 3rd quarter valued at $27,000. 77.09% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

SYK has been the subject of a number of research reports. UBS Group assumed coverage on shares of Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price target for the company. Raymond James Financial set a $370.00 price objective on shares of Stryker in a report on Friday, July 31st. Truist Financial upped their price objective on shares of Stryker from $330.00 to $340.00 and gave the company a “hold” rating in a research report on Friday, July 31st. JPMorgan Chase & Co. reduced their target price on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Finally, Citigroup reissued a “buy” rating on shares of Stryker in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

Stryker Price Performance

Stryker stock opened at $329.86 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a market capitalization of $126.52 billion, a PE ratio of 34.18, a price-to-earnings-growth ratio of 2.10 and a beta of 0.76. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The business has a 50 day simple moving average of $326.99 and a 200 day simple moving average of $332.64.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. During the same period in the prior year, the business posted $3.13 earnings per share. The business’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, sell-side analysts forecast that Stryker Corporation will post 15.02 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s payout ratio is currently 36.48%.

Insider Transactions at Stryker

In related news, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the sale, the vice president owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Debra King sold 826 shares of Stryker stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the transaction, the insider directly owned 6,210 shares of the company’s stock, valued at $2,088,423. This represents a 11.74% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 665,370 shares of company stock valued at $216,238,501. 4.60% of the stock is owned by insiders.

Stryker News Summary

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Stryker’s long-term outlook remains supported by steady demand for its medical technologies, continued Mako robotics growth and improving margins. The company’s latest quarter exceeded expectations, with earnings of $3.69 per share on $6.59 billion in revenue, while revenue increased 9.4% year over year. Here’s Why You Should Hold Stryker Stock in Your Portfolio for Now
• Positive Sentiment: Wall Street remains broadly constructive: consensus calls for a “Moderate Buy” rating, with 18 analysts recommending Buy or Strong Buy versus six Holds. The average target of $386.28 implies meaningful upside from recent trading levels, although several firms have lowered their individual targets. Are Wall Street Analysts Predicting Stryker Stock Will Climb or Sink?
• Neutral Sentiment: Stryker maintained its fiscal 2026 earnings guidance of $14.95 to $15.10 per share and recently declared a quarterly dividend of $0.88, equivalent to a 1.1% annual yield. Institutional ownership remains high at approximately 77%, indicating continued support from large investors.
• Negative Sentiment: Director Ronda Stryker sold a combined 350,000 shares for approximately $117.8 million across August 18–19. Although she still owns more than 2.25 million shares, the transactions reduced her direct ownership and may raise caution among investors. Stryker Director Sells Shares
• Negative Sentiment: Recent commentary highlights execution risks, including cyber and supply-chain disruptions, while analysts have trimmed targets after an imperfect second quarter. BTIG reduced its target to $358 and JPMorgan lowered its target to $350, contributing to near-term pressure despite their Buy and Overweight ratings. Stryker Sell-Off Analysis

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.